Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Deloitte
Federal Trade Commission
Moodys
Baxter
Queensland Health

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 10,183,994

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,183,994
Title:Anti-TNF.alpha. antibodies with pH-dependent antigen binding for improved target clearence
Abstract: The invention relates to anti-TNF.alpha. antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNF.alpha. antibody adalimumab (Humira.RTM.) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
Inventor(s): Guenther; Ralf (Griesheim, DE), Becker; Stefan (Darmstadt, DE), Rhiel; Laura (Frankfurt am Main, DE), Hock; Bjoern (Maintal, DE), Schroeter; Christian (Darmstadt, DE)
Assignee: Merck Patent GmbH (Darmstadt, DE)
Application Number:15/322,893
Patent Claims:see list of patent claims

Details for Patent 10,183,994

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Sign Up Merck Patent GmbH (Darmstadt, DE) 2034-06-30 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31 ➤ Sign Up Merck Patent GmbH (Darmstadt, DE) 2034-06-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Boehringer Ingelheim
Citi
McKesson
QuintilesIMS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.